SZTAKI researchers are participating in the Horizon 2020 AIDPATH international project, which aims to promote personalized CAR-T therapies using artificial intelligence and the latest findings in production planning and scheduling. The results will be used in the fields of hematology and oncology and the treatment of infectious and autoimmune diseases.
The AIDPATH (Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital) EU H2020 consortium aims to support next-generation, personalized treatment in Europe's hospitals with artificial intelligence tools. The subject of these research, development and innovation activities is CAR-T cell therapy, which has already proven itself in hematology and oncology treatment, and is expected also to be used in the future to treat infectious and autoimmune diseases.
Conventional CAR-T cell therapy is hindered by several different factors. Today’s procedures largely ignore the patient’s condition and the individual characteristics of the cells to be treated. The production – or manufacture – of the cells is uncertain, and the central laboratory can only serve hospitals through very complex logistical processes.
The AIDPATH project aims to develop personalized therapies that take better account of patient-specific data and biomarkers in T-cell therapy, as well as the use of flexible manufacturing processes to produce the most appropriate T-cell stock for patients. Artificial intelligence methods are used in every stage of treatment, and state-of-the-art production planning and scheduling are also used to make the best use of hospital resources.
SZTAKI is represented in the four-year AIDPATH project by the Research Laboratory on Engineering & Management Intelligence (EMI). The direct precedent of the successful H2020 application was a bilateral medical and IT research study for stem cell production conducted by the German institute heading the consortium and the SZTAKI EMI laboratory as part of the SZTAKI-led EPIC Centre of Excellence in Production Informatics and Control. The Hungarian leader of the AIDPATH project is Dr. Tamás Kis, a scientific advisor for SZTAKI.
The consortium leader of the AIDPATH project is German Fraunhofer IPT (Fraunhofer-Institut für Produktionstechnologie), the academic partners are SZTAKI, Fraunhofer IZI (Institut für Zelltherapie und Immunologie), University College London, Idryma Technologias Kai Erevnas (FORTH) Univaersitatsklinikum Würzburg and the Fundacio Clinic per a la Recerca. Non-academic partners include Algaris Cell, Irvine Scientific, Hitachi Chemical Advanced Therapeutics, IRIS Technology Solutions, Red Alerts Labs, Panaxea, and ORTEC Optimization Technology B.V..
